H.C. Wainwright raised the firm’s price target on Legend Biotech to $87 from $86 and keeps a Buy rating on the shares. The analyst says the company’s deal with Novartis to advance Legend’s delta-like ligand protein 3 targeted CAR-T therapy candidates validates its CAR-T design.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEGN:
- Legend to get $100M from Novartis in license pact for CAR-T therapy for DLL3
- Legend Biotech initiated with a Buy at Goldman Sachs
- Arcellx initiated with an Outperform at TD Cowen
- Legend Biotech price target raised to $86 from $85 at H.C. Wainwright
- Legend Biotech price target raised to $93 from $92 at Barclays
